Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: a year in review

Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese-Krott, M., Kendall, D. A., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri Jr, R. A., Patel, H. H., Schulz, R., Stefanska, B., Stephens, G. J. ORCID: https://orcid.org/0000-0002-8966-4238, Teixeira, M. M., Vergnolle, N., Wang, X. and Ferdinandy, P. (2024) Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: a year in review. British Journal of Pharmacology. ISSN 1476-5381 doi: 10.1111/bph.16337

Abstract/Summary

In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer. Thirty drugs are categorized as "first-in-class" (FIC), illustrating the quality of research and innovation that drives new chemical entity discovery and development. We succinctly describe the mechanism of action of most of these FIC drugs and discuss the therapeutic areas covered, as well as the chemical category to which these drugs belong. The 2023 novel drug list also demonstrates an unabated emphasis on polypeptides (recombinant proteins and antibodies), Advanced Therapy Medicinal Products (gene and cell therapies) and RNA therapeutics, including the first-ever approval of a CRISPR-Cas9-based gene-editing cell therapy.

Item Type	Article
URI	https://reading-clone.eprints-hosting.org/id/eprint/115867
Identification Number/DOI	10.1111/bph.16337
Refereed	Yes
Divisions	Interdisciplinary Research Centres (IDRCs) > Centre for Integrative Neuroscience and Neurodynamics (CINN) Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
Publisher	Wiley
Download/View statistics	View download statistics for this item